Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fry, W. A.
Right arrow Articles by Khandekar, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fry, W. A.
Right arrow Articles by Khandekar, J. D.

Annals of Surgical Oncology, Vol 2, Issue 2 160-164, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Parietal pleurectomy for malignant pleural effusion

W. A. Fry and J. D. Khandekar
Section of Thoracic Surgery, Evanston Hospital, Northwestern University Medical School, Illinois, USA.

BACKGROUND: Malignant pleural effusions are seen frequently in clinical practice and are most commonly caused by breast cancer and lung cancer. Standard treatment usually consists of complete drainage of the pleural space via a chest tube and instillation of a pleural irritant to obtain pleural symphysis. In a majority of instances, such treatment effectively controls the pleural space; however, standard treatment fails in some cases. METHODS: Twenty-four patients who did not respond to standard treatment for malignant pleural effusion were subjects for parietal pleurectomy, which was usually performed through an axillary thoracotomy. In several cases, decortication was also necessary. The study population was composed of 18 women and six men. Twelve of the patients had carcinoma of the breast, five carcinoma of the lung, and four carcinoma of the ovary. RESULTS: Three patients died in the perioperative period to give an operative mortality of 12.5%. The other 21 patients all had satisfactory control of their recurrent malignant effusions. Their survival time ranged from 2 to 30 months (average 10.6). CONCLUSIONS: Parietal pleurectomy is an effective operation for recurrent malignant pleural effusion. However, because of its significant morbidity and mortality, it should be reserved for failures of standard treatment, and patient selection is important.


This article has been cited by other articles:


Home page
 ChestHome page
P. A. Kvale, P. A. Selecky, and U. B. S. Prakash
Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 368S - 403S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
F. Rodriguez-Panadero, J. P. Janssen, and P. Astoul
Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion.
Eur. Respir. J., August 1, 2006; 28(2): 409 - 422.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Tan, A. Sedrakyan, J. Browne, S. Swift, and T. Treasure
The evidence on the effectiveness of management for malignant pleural effusion: a systematic review.
Eur. J. Cardiothorac. Surg., May 1, 2006; 29(5): 829 - 838.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A Medford and N Maskell
Pleural effusion
Postgrad. Med. J., November 1, 2005; 81(961): 702 - 710.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G Antunes, E Neville, J Duffy, and N Ali
BTS guidelines for the management of malignant pleural effusions
Thorax, May 1, 2003; 58(90002): ii29 - 38.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
D. B. Campbell
Malignant Mesothelioma
Ann. Thorac. Surg., May 1, 1997; 63(5): 1503 - 1505.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.